A recently conducted clinical trial by the University of Cincinnati showed that by adding an immunotherapy drug to the standard of care treatment regimens, the survival rates for head and neck cancer patients with intermediate-risk features has increased.
A University of Cincinnati clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.
A recently conducted clinical trial by the University of Cincinnati showed that by adding an immunotherapy drug to the standard of care treatment regimens, the
A recently conducted clinical trial by the University of Cincinnati showed that by adding an immunotherapy drug to the standard of care treatment regimens, the survival rates for head and neck cancer patients with intermediate-risk features has increased.
A clinical trial that added an immunotherapy drug to standard of care treatment regimens has shown increased survival rates for head and neck cancer patients with intermediate risk features.